Posted:
1/7/2026, 2:30:04 PM
Location(s):
Shanghai, China ⋅ Shanghai, Shanghai, China
Experience Level(s):
Senior
Field(s):
Finance & Banking
JOB SUMMARY
The R&D Innovation Lead reports to the Head of APAC, Global R&D and is responsible to lead the Open Innovation Center (OIC) activities in China. The OIC is a collaborative hub focused on knowledge sharing, consultation, and strategic partnerships in drug development with local biotech companies, academic institutions, hospitals, and governments. The role will have direct operational oversight and responsibilities for the OIC activities, which will be conducted in collaboration with relevant functions in Development China, R&D, and Business Development as well as Medical Affairs and Commercial in China. The R&D Innovation Lead will enhance Pfizer’s position as a trusted multinational company advancing innovation by showcasing the complete scope and commitment of the company’s R&D engagement in China, including the progress of the development portfolio, to external stakeholders. The role will also serve as a member of the OIC Steering Committee that will provide strategic oversight and decision-making and ensure alignment with enterprise goals.
JOB RESPONSIBILITIES
The R&D Innovation Lead will have direct operational oversight and responsibilities for the OIC activities, which will be conducted in collaboration with relevant functions in Development China, R&D, and Business Development as well as Medical Affairs and Commercial in China:
Lead the two OICs established in Beijing and Shanghai to execute the projects launched and fulfill the key performance indicators aligned with local governments and healthcare stakeholders. Below are examples of the projects.
QUALIFICATIONS / SKILLS
Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates.
MedicalWebsite: https://www.pfizer.com/
Headquarter Location: New York, New York, United States
Employee Count: 10001+
Year Founded: 1849
IPO Status: Public
Last Funding Type: Post-IPO Debt
Industries: Biotechnology ⋅ Health Care ⋅ Medical ⋅ Pharmaceutical ⋅ Precision Medicine